FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559045020> ?p ?o ?g. }

• W2559045020 abstract "Abstract The role of maintenance therapy for the long term control of the plasma cell clone in patients induced into response with either intensive or conventional treatment is an important outstanding question. We addressed this in the MRC Myeloma IX study which incorporates intensive and non-intensive pathways selected according to PS and age. In the intensive pathway patients were randomised to either CTD or CVAD induction, followed by High Dose Melphalan (HDM) before being randomised to either thalidomide or no maintenance. In the non-intensive pathway patients were randomised to either MP or attenuated CTD prior to the maintenance randomisation. For patients randomised to thalidomide it was initiated at d100 following HDM or at the end of induction in the non-intensive arm with the aim of delivering 100mg daily until relapse. A dose reduction algorithm for side effects was used. Between the years of 2003–8, 820 patients were entered into the maintenance randomisation, median age 64 (intensive 59, non-intensive 73), median follow-up 32 months. Prognostic features were evenly distributed between the arms. FISH and cytogenetics were done using standard methods. Response was assessed by IWG criteria. For overall survival (OS) there was a non-significant trend in favour of the no maintenance arm, which enables us, by calculating confidence limits on the hazard ratio, to make the assertion that no maintenance could be up to 7% worse than thalidomide at 5 years (p=.005). Further analysis showed that there was no significant difference in OS in either the intensive or the non-intensive arm. The duration of time on thalidomide maintenance appeared to make no difference to OS. There was a non-significant improvement in progression free survival (PFS) across the maintenance randomisation as a whole and in the intensive pathway a significant benefit of maintenance was seen in the patients achieving less than a VGPR post initial induction therapy prior to HDM, (hazard ratio 1.9, p=.007). This PFS difference did not translate into a survival benefit because the survival after progression in the PR patients receiving maintenance thalidomide was poor (p=.002). In addition we looked at the time spent off thalidomide, the recovery time, (the time between stopping thalidomide and progression) as a possible predictor of survival after progression. Treated as a continuous variable in the Cox model this showed a trend for longer survival after relapse in those with longer recovery time (p=.056). In the non-intensive pathway a similar but less pronounced effect of thalidomide maintenance on PFS was seen. These results are consistent with a consolidation rather than a maintenance effect for thalidomide in this setting. The impact of maintenance in different cytogenetic subgroups was also determined [17p-, 13q-, 14q abnormalities including t(4;14), t(14;16), t(6;14), t(14;20) and t(11;14)]. For the 17p- group, the difference in OS between no thalidomide and thalidomide is large (HR = 4.55, p=.02) with the thalidomide patients faring worse, although this is based on only 30 patients. For the non 17p- group there is no difference in PFS (HR = 1.24, p=.37), in the 17p- group, however, the PFS is worse. In addition, of the 22, 17p- patients receiving CTD or CTDa as initial therapy, the 10 who received no thalidomide maintenance are all still alive, whereas 9/12 of those who went on to receive thalidomide maintenance have died. It seems that thalidomide given at induction and again in maintenance, may be particularly detrimental in 17p- patients. Although thalidomide maintenance may improve PFS, there is no demonstrable benefit on OS. It is important to identify 17p- in order to exclude these patients from receiving thalidomide maintenance." @default.
• W2559045020 created "2016-12-08" @default.
• W2559045020 creator A5003687947 @default.
• W2559045020 creator A5010220334 @default.
• W2559045020 creator A5016246851 @default.
• W2559045020 creator A5017165070 @default.
• W2559045020 creator A5017554622 @default.
• W2559045020 creator A5034560778 @default.
• W2559045020 creator A5053100242 @default.
• W2559045020 creator A5063301766 @default.
• W2559045020 creator A5081247376 @default.
• W2559045020 creator A5085134973 @default.
• W2559045020 creator A5088173364 @default.
• W2559045020 date "2008-11-16" @default.
• W2559045020 modified "2023-09-26" @default.
• W2559045020 title "Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation" @default.
• W2559045020 doi "https://doi.org/10.1182/blood.v112.11.656.656" @default.
• W2559045020 hasPublicationYear "2008" @default.
• W2559045020 type Work @default.
• W2559045020 sameAs 2559045020 @default.
• W2559045020 citedByCount "36" @default.
• W2559045020 countsByYear W25590450202012 @default.
• W2559045020 countsByYear W25590450202013 @default.
• W2559045020 countsByYear W25590450202014 @default.
• W2559045020 countsByYear W25590450202023 @default.
• W2559045020 crossrefType "journal-article" @default.
• W2559045020 hasAuthorship W2559045020A5003687947 @default.
• W2559045020 hasAuthorship W2559045020A5010220334 @default.
• W2559045020 hasAuthorship W2559045020A5016246851 @default.
• W2559045020 hasAuthorship W2559045020A5017165070 @default.
• W2559045020 hasAuthorship W2559045020A5017554622 @default.
• W2559045020 hasAuthorship W2559045020A5034560778 @default.
• W2559045020 hasAuthorship W2559045020A5053100242 @default.
• W2559045020 hasAuthorship W2559045020A5063301766 @default.
• W2559045020 hasAuthorship W2559045020A5081247376 @default.
• W2559045020 hasAuthorship W2559045020A5085134973 @default.
• W2559045020 hasAuthorship W2559045020A5088173364 @default.
• W2559045020 hasConcept C126322002 @default.
• W2559045020 hasConcept C168563851 @default.
• W2559045020 hasConcept C177713679 @default.
• W2559045020 hasConcept C207103383 @default.
• W2559045020 hasConcept C2776364478 @default.
• W2559045020 hasConcept C2776694085 @default.
• W2559045020 hasConcept C2778283404 @default.
• W2559045020 hasConcept C2778524551 @default.
• W2559045020 hasConcept C2778684742 @default.
• W2559045020 hasConcept C2779609412 @default.
• W2559045020 hasConcept C2987404301 @default.
• W2559045020 hasConcept C44249647 @default.
• W2559045020 hasConcept C61943457 @default.
• W2559045020 hasConcept C71924100 @default.
• W2559045020 hasConceptScore W2559045020C126322002 @default.
• W2559045020 hasConceptScore W2559045020C168563851 @default.
• W2559045020 hasConceptScore W2559045020C177713679 @default.
• W2559045020 hasConceptScore W2559045020C207103383 @default.
• W2559045020 hasConceptScore W2559045020C2776364478 @default.
• W2559045020 hasConceptScore W2559045020C2776694085 @default.
• W2559045020 hasConceptScore W2559045020C2778283404 @default.
• W2559045020 hasConceptScore W2559045020C2778524551 @default.
• W2559045020 hasConceptScore W2559045020C2778684742 @default.
• W2559045020 hasConceptScore W2559045020C2779609412 @default.
• W2559045020 hasConceptScore W2559045020C2987404301 @default.
• W2559045020 hasConceptScore W2559045020C44249647 @default.
• W2559045020 hasConceptScore W2559045020C61943457 @default.
• W2559045020 hasConceptScore W2559045020C71924100 @default.
• W2559045020 hasLocation W25590450201 @default.
• W2559045020 hasOpenAccess W2559045020 @default.
• W2559045020 hasPrimaryLocation W25590450201 @default.
• W2559045020 hasRelatedWork W1988092780 @default.
• W2559045020 hasRelatedWork W1992538067 @default.
• W2559045020 hasRelatedWork W2021954218 @default.
• W2559045020 hasRelatedWork W2066800926 @default.
• W2559045020 hasRelatedWork W2082741854 @default.
• W2559045020 hasRelatedWork W2088540908 @default.
• W2559045020 hasRelatedWork W2093757149 @default.
• W2559045020 hasRelatedWork W2096207943 @default.
• W2559045020 hasRelatedWork W2101576302 @default.
• W2559045020 hasRelatedWork W2102591890 @default.
• W2559045020 hasRelatedWork W2108601475 @default.
• W2559045020 hasRelatedWork W2110466835 @default.
• W2559045020 hasRelatedWork W2117172636 @default.
• W2559045020 hasRelatedWork W2121399230 @default.
• W2559045020 hasRelatedWork W2135514413 @default.
• W2559045020 hasRelatedWork W2136373453 @default.
• W2559045020 hasRelatedWork W2146607984 @default.
• W2559045020 hasRelatedWork W2151989390 @default.
• W2559045020 hasRelatedWork W2169336006 @default.
• W2559045020 hasRelatedWork W2333363976 @default.
• W2559045020 isParatext "false" @default.
• W2559045020 isRetracted "false" @default.
• W2559045020 magId "2559045020" @default.
• W2559045020 workType "article" @default.